Making Cents out of nothing
Followers | 426 |
Posts | 18,415 |
Boards Moderated | 2 |
Alias Born | 06/03/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very nice
MrK
$PURO going way higher IMO
Nice news today
MrK
$PURO huge upside here. Charts are primed
MrK
Looking good now
MrK
$PURO
No doubt. Nice SS here
$UATG
MrK
Looking good
LOI here and assuming the updates still coming I'd prefer to accumulate cheaper ahead of the pending news/updates. Always newbies to gift shares ahead rather than having the patience to load the big wins
MrK
$PMPG will get bought up here
$PURO looking better here
Awaiting updates
MrK
Strong play here
MrK
Loaded the boat here
MrK
$GMGI
Indeed
MrK
$PMPG
Smart move putting casino and crypto together lol
MrK
$GMGI
I've had TD account for years and customized.
Its free to download I believe
I agree..
Would think news imminent.
Holding with patience.
$UATG
MrK
$GMGI thinning out the higher she goes
MrK
$GMGI can be a sweet runner IMO
MrK
Seems like a nice move
MrK
$GMGI
$GMGI interesting Crypto + Las Vegas
MrK
$ITUS Corporation Terminates At-The-Market Offering
7:00 AM ET 12/12/17 | PR Newswire
RELATED QUOTES
10:17 AM ET 1/9/18
Symbol Last % Chg
ITUS
3.91 30.85%
Real time quote.
SAN JOSE, Calif., Dec. 12, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), announced today that it has terminated its at-the-market equity program ("ATM Offering") with B. Riley FBR, Inc. The Company had not sold any shares, and will no longer offer any shares, under this program.
"With over a year's worth of cash based on our current business plan and many exciting opportunities ahead of us, we no longer feel that the ATM Offering is necessary," stated Dr. Amit Kumar, President and Chief Executive Officer of ITUS. "While the continued development of Cchek(TM) and commencement of our ovarian cancer CAR-T therapeutic program will require additional resources, we believe that we are in a position to support both programs in the near term and that our longer-term needs will be better addressed through strategic partnerships and other corporate transactions," added Dr. Kumar.
ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the Cchek(TM) platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.ITUScorp.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
ITUS Corporation: FOCUSED ON INNOVATION(TM)
View original content with multimedia:http://www.prnewswire.com/news-releases/itus-corporation-terminates-at-the-market-offering-300569857.html
SOURCE ITUS Corporation
/CONTACT: Investor Relations and Media contact: Michael Volpatt, Larkin/Volpatt Communications, (415) 994-8864, Michael@LarkinVolpatt.com or Company contact: Mike Catelani, (408) 708-9808, MCatelani@ITUScorp.com
/Web site: https://www.ituscorp.com
> Dow Jones Newswires
December 12, 2017 07:00 ET (12:00 GMT)
$ITUS Corporation Terminates At-The-Market Offering
7:00 AM ET 12/12/17 | PR Newswire
RELATED QUOTES
10:17 AM ET 1/9/18
Symbol Last % Chg
ITUS
3.91 30.85%
Real time quote.
SAN JOSE, Calif., Dec. 12, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), announced today that it has terminated its at-the-market equity program ("ATM Offering") with B. Riley FBR, Inc. The Company had not sold any shares, and will no longer offer any shares, under this program.
"With over a year's worth of cash based on our current business plan and many exciting opportunities ahead of us, we no longer feel that the ATM Offering is necessary," stated Dr. Amit Kumar, President and Chief Executive Officer of ITUS. "While the continued development of Cchek(TM) and commencement of our ovarian cancer CAR-T therapeutic program will require additional resources, we believe that we are in a position to support both programs in the near term and that our longer-term needs will be better addressed through strategic partnerships and other corporate transactions," added Dr. Kumar.
ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the Cchek(TM) platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.ITUScorp.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
ITUS Corporation: FOCUSED ON INNOVATION(TM)
View original content with multimedia:http://www.prnewswire.com/news-releases/itus-corporation-terminates-at-the-market-offering-300569857.html
SOURCE ITUS Corporation
/CONTACT: Investor Relations and Media contact: Michael Volpatt, Larkin/Volpatt Communications, (415) 994-8864, Michael@LarkinVolpatt.com or Company contact: Mike Catelani, (408) 708-9808, MCatelani@ITUScorp.com
/Web site: https://www.ituscorp.com
> Dow Jones Newswires
December 12, 2017 07:00 ET (12:00 GMT)
I like em wild
MrK
I thought, lol all good. Demand is obvious
MrK
$PMPG
Looking good here
MrK
The demand is here no doubt
MrK
$PMPG
VERY
$GRDO
MrK
Yup, there it is lol
MrK
Don't forget the meatballs
MrK
Yes very very good news imo
MrK
Nice one
MrK
.10 cents looking very sexy up there all by its lonesome
After this break nothing in the way of overhang IMO
$PMPG
MrK
Looking very good